The objectives of this post market registry are to evaluate the safety and durability of treatment effect up to 3 years following cross-linking performed with Photrexa Viscous (riboflavin 5'- phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'- phosphate ophthalmic solution), and the KXL System in patients with corneal ectasia following refractive surgery.
Approximately 200 patients who are planning to undergo or have undergone CXL for the treatment of corneal ectasia following refractive surgery in one or both eyes according to the prescribing information in the Photrexa Viscous and Photrexa Package Insert could be enrolled. Patients will be followed for safety and effectiveness at Months 3, 6, 12, 24 and 36 following cross-linking treatment.
Study Type
OBSERVATIONAL
Enrollment
200
Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
Stanford University School of Medicine
Palo Alto, California, United States
RECRUITINGChu Vision Institute, P.A.
Bloomington, Minnesota, United States
RECRUITINGKmax
Change from pretreatment baseline in maximum corneal curvature
Time frame: 36 months
BCVA
Change from pretreatment baseline in BCVA
Time frame: 36 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Vance Thompson Vision - MT
Bozeman, Montana, United States
RECRUITINGVance Thompson Vision - ND
West Fargo, North Dakota, United States
RECRUITINGComprehensive EyeCare of Central Ohio
Westerville, Ohio, United States
RECRUITINGVantage Eye Care, LLC
Bala-Cynwyd, Pennsylvania, United States
RECRUITINGCarolina Cataract & Laser Center
Ladson, South Carolina, United States
RECRUITINGSlade & Baker Vision
Houston, Texas, United States
RECRUITINGHoopes Vision
Draper, Utah, United States
RECRUITINGSee Clearly Vision Group
McLean, Virginia, United States
RECRUITING...and 1 more locations